2 speculative penny stocks I’m thinking about buying

I’m hunting for cheap UK shares packed with potential for the next decade. Here are two top penny stocks I think could be top buys for me.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I think Scancell Holdings (LSE: SCLP) could be great penny stock to buy as the Covid-19 crisis stretches on. News flow coming from this cheap UK healthcare share on the development of a coronavirus vaccine has remained extremely positive.

Yet its share price has continued to trade basically sideways for the past six months. An update on testing in the second half could light a fire under the pharma play’s share price again.

Of course, buying drugs developers can be high risk. There’s no guarantee trials will come back positive, in this case neither for the testing of said vaccine later in 2021, nor for its other products used to treat cancer and infectious diseases.

But at the moment, news flow surrounding its Covid-19 battler for one continues moving in the right direction. South Africa signed off for Phase 1 clinical trials to begin late last month.

Packed with potential

I think Scancell could be considered to be a very speculative buy. But if it gets things right, the rewards for investors could be considerable. As for Covid-19, analysts at McKinsey & Company predict the pandemic will drag on for the next few years, at least. And, pleasingly for the likes of Scancell, they anticipate “it is likely that some measures such as booster vaccines are likely to be required indefinitely.”

Scancell’s work in the fast-growing fields of oncology and infectious diseases also offers plenty to be encouraged by. Although it’s worth noting City brokers don’t expect the penny stock to turn a profit for the next few years at least. Drugs R&D is expensive business, and Scancell may well be forced to tap shareholders for cash before too long.

Another exciting penny stock

Powerhouse Energy Group’s (LSE: PHG) another penny stock packed with potential. The escalating climate crisis means legislators are accelerating plans to further their green agendas. And this plays into the hands of this UK energy share.

Powerhouse has developed proprietary technology than turns discarded plastic, tyres and other waste items into clean energy, in this case a hydrogen-rich gas.

Hydrogen is one area of energy in which lawmakers are stepping up investment. In the UK, for instance, the government plans to develop 5 gigawatts of low-carbon hydrogen production capacity by 2030. Analysts at Bank of America think hydrogen will take 25% of global oil demand by 2050.

This doesn’t mean Powerhouse Energy is a slam dunk for those seeking to ride the green revolution, of course. Okay, the penny stock generated its first-ever revenues in 2020, thanks to initial engineering work on the Protos energy recovery facility in Cheshire.

But this line of work is naturally complex and expensive. So any problems with getting its technologies up and running (it’s hoped Protos will be working by 2022) could hammer its sales expectations and force it to ask investors for cash.

Still, like Scancell, I think this penny stock’s still worth serious attention today.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

The key number that could signal a recovery for the Greggs share price in 2026

The Greggs share price has crashed in 2025, but is the company facing serious long-term challenges or are its issues…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

Can the Rolls-Royce share price hit £16 in 2026? Here’s what the experts think

The Rolls-Royce share price has been unstoppable. Can AI data centres and higher defence spending keep the momentum going in…

Read more »

Businessman with tablet, waiting at the train station platform
Investing Articles

Up 150% in 5 years! What’s going on with the Lloyds share price?

The Lloyds share price has had a strong five years. Our writer sees reasons to think it could go even…

Read more »

Investing Articles

Where will Rolls-Royce shares go in 2026? Here’s what the experts say!

Rolls-Royce shares delivered a tremendous return for investors in 2025. Analysts expect next year to be positive, but slower.

Read more »

Emma Raducanu for Vodafone billboard animation at Piccadilly Circus, London
Investing Articles

Up 40% this year, can the Vodafone share price keep going?

Vodafone shareholders have been rewarded this year with a dividend increase on top of share price growth. Our writer weighs…

Read more »

Buffett at the BRK AGM
Investing Articles

Here’s why I like Tesco shares, but won’t be buying any!

Drawing inspiration from famed investor Warren Buffett's approach, our writer explains why Tesco shares aren't on his shopping list.

Read more »

Investing For Beginners

If the HSBC share price can clear these hurdles, it could fly in 2026

After a fantastic year, Jon Smith points out some of the potential road bumps for the HSBC share price, including…

Read more »

Investing Articles

I’m thrilled I bought Rolls-Royce shares in 2023. Will I buy more in 2026?

Rolls-Royce has become a superior company, with rising profits, buybacks, and shares now paying a dividend. So is the FTSE…

Read more »